Risperidone
- PDF / 130,575 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 88 Downloads / 188 Views
1
S
Rhabdomyolysis: 5 case reports Three males and two females aged 16–54 years developed rhabdomyolysis during treatment with risperidone [routes and indications not stated]. Four patients received a total daily dose of risperidone ranging from 0.5 to 4.5mg at the time of reaction onset. The total daily dose for the fifth patient was unknown. The onset of rhabdomyolysis occurred between 17 days and 10 years from the start of treatment with risperidone in the five patients. One patient was also being treated with concomitant irbesartan and another patient was receiving valsartan. The range of the peak serum creatine phosphokinase level was 1023–39 000 IU/L. Risperidone was discontinued in all five patients. After withdrawal of the drug, a negative dechallenge was recorded in one patient and a positive dechallenge was recorded for the remaining four patients. At the time of reporting, four patients had recovered and there had been no deaths. Author comment: "Health Canada received 5 reports of rhabdomyolysis independent of [neuroleptic malignant syndrome] suspected of being associated with risperidone". Chou S, et al. Risperidone and rhabdomyolysis independent of neuroleptic malignant syndrome. Canadian Adverse Reaction Newsletter 23: 2-3, No. 1, Jan 803083585 2013. Available from: URL: http://www.hc-sc.gc.ca - Canada
0114-9954/10/1440-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 23 Feb 2013 No. 1440
Data Loading...
